Boehringer and Zealand want to outperform Novo and are comparing their obesity treatment to semaglutid

Boehringer Ingelheim and Zealand Pharma are collaborating to develop an obesity treatment, which they are comparing to semaglutid in a new phase II study. The treatment is a potential future winner, says Zealand Pharma.

Emmanuel Dulac, CEO at Zealand Pharma Photo: Zealand Pharma / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles